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dichotomy has recently been observed 
in other vascular beds with ACE inhibi-
tion in type 1 diabetic mice.15 Perhaps, 
in glomerular injury, inhibition of 
endothelial-cell contact — or, in renal 
development, incomplete establishment 
of a contiguous endothelial-cell layer — 
dictates the actions of angiotensin and 
hence ACE inhibition.
Hopefully, this Commentary will 
stimulate the reader to wonder about 
how ACE inhibition (or AT1R block-
ade) can on the one hand actually repair 
some diseased kidneys but on the other 
hand interfere with normal renal devel-
opment or the recovery of other dis-
eased kidneys. Certainly studies such as 
those by Dr. Remuzzi and his colleagues 
should not be dismissed as being about 
‘just another rat with proteinuria that’s 
cured by ACE inhibition’.
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Non-Pseudomonas Gram-negative organisms account for over 10% 
of cases of peritoneal dialysis-associated peritonitis. The key findings 
from a paper by Szeto et al. are discussed and compared with those 
from previous publications. This type of peritonitis has a high rate of 
catheter removal and technique failure. Results may be better with 
more aggressive antibiotic treatment. Other developments in the field 
are reviewed.
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Th e superiority of the well-done ran-
domized controlled trial over all other 
forms of clinical studies is widely 
accepted and understood. However, the 
relative rarity of such trials in the dialy-
sis literature is also well recognized. 
Th ere are many areas of dialysis practice 
where randomized trials have not been 
carried out or are not feasible. Th ere-
fore, the continuing importance of other 
forms of clinical investigations should 
not be forgotten. Th is includes the old-
fashioned retrospective review of clini-
cal experience with a large number of 
cases of a given condition. Th e article 
by Szeto et al.1 in this issue is an excel-
lent example.
Th e topic is peritoneal dialysis (PD)-
related peritonitis due to Enterobac-
teriaceae organisms. Th e investigators 
review a decade’s experience in a single 
large Hong Kong center with a total of 
210 cases. This is the largest reported 
series to date of cases of what is some-
times termed non-Pseudomonas Gram-
negative (NPGN) peritonitis.2 Th e paper 
provides a wealth of important and 
helpful clinical observations, and, taken 
together with two earlier papers from the 
Unites States, it enhances our knowledge 
of this important condition.2,3
Peritonitis remains the single big-
gest cause of technique failure in PD. 
Advances over the past two decades 
in connectology and in Staphylococ-
cus aureus prophylaxis have led to 
impressive decreases in the rates of 
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Gram-positive peritonitis.4 However, 
the incidence of Gram-negative perito-
nitis appears hardly to have changed at 
all and so has become proportionately 
more important.3 Furthermore, such 
cases are oft en more severe and associ-
ated with worse outcomes, including 
catheter loss, technique failure, and even 
death. It would be fair to say that there 
has been some pessimism in the PD com-
munity about the possibility of decreasing 
Gram-negative peritonitis rates. In part, 
this is because many of these cases, espe-
cially those due to NPGN organisms, are 
thought to result from transmigration of 
enteric organisms across the bowel, and 
an eff ective strategy to prevent this has 
not been apparent. Th ere is, however, an 
increasing awareness that many NPGN 
infections occur via the same routes of 
touch contamination and pericatheter 
migration that are so important for Gram-
positive and Pseudomonas peritonitis.
Szeto et al.1 found that 12% of all their 
peritonitis cases were related to Entero-
bacteriaceae, a slightly higher fi gure than 
that reported in earlier studies by North 
American investigators, but consistent 
with the rising proportion of perito-
nitis due to Gram-negative organisms 
in more recent papers.3,4 They found 
that 85% of their cases of NPGN peri-
tonitis responded to treatment, but that 
some soon relapsed and just under 60% 
achieved a complete cure. Th e latter fi g-
ure is almost identical to that reported 
by Bunke et al. for NPGN peritonitis in 
a United States multicenter series dating 
back to 1991.2 Concurrent exit site or tun-
nel infection was found in 18% of cases, 
even though most of these infections 
were not due to the same organism that 
caused the peritonitis. Th is is very simi-
lar to the 16% reported by Bunke et al., 
and, as has been shown before for other 
types of peritonitis, these cases were more 
likely to result in catheter removal and 
technique failure.2–4 Additional predic-
tors of an unsuccessful response — either 
initially or eventually — included previ-
ous antibiotic therapy, use of only one 
antibiotic to treat the peritonitis, and use 
of an aminoglycoside versus a third- or 
fourth-generation cephalosporin.
Szeto et al.’s most clinically important 
finding is the lower relapse rate with 
the use of two antibiotics versus one.1 It 
might have been predicted that cases for 
which the physician prescribed two anti-
biotics would have been inherently more 
severe. Th e superior outcome with two 
antibiotics is therefore surprising, and 
although it is a retrospective observation 
with the possibility for unexplained con-
founding, it is encouraging. It suggests 
that the infl uential International Society 
for Peritoneal Dialysis recommendations 
on treatment of peritonitis may be unduly 
conservative in advocating only one agent 
for NPGN cases.5 Findings from Hong 
Kong may not always be applicable to 
other populations, especially in view of 
the widespread, poorly regulated com-
munity use of antibiotics in that juris-
diction. However, strong consideration 
should now be given to early introduc-
tion of a second antibiotic in all cases of 
NPGN peritonitis.
Overall, Szeto et al.’s paper1 reminds us 
again that NPGN peritonitis is a severe 
illness with rates of catheter loss and 
technique failure greater than those for 
peritonitis due to S. aureus, though less 
than those for cases due to fungi and 
Pseudomonas. Furthermore, mortality at 
1 month in this series was a sobering 10%. 
Th e reasons for this poor outcome are not 
altogether clear but are probably related to 
the inherent virulence of these organisms, 
their ability to protect themselves from 
antibiotics in catheter biofi lm, and their 
association in a significant number of 
cases with intra-abdominal pathologies, 
such as bowel perforation. Insuffi  ciently 
aggressive initial antibiotic therapy may 
also be a factor. Another possibility is 
that the occurrence of NPGN peritonitis 
is a marker of an inherently less healthy 
patient, but this is not supported by either 
Szeto et al.’s or Bunke et al.’s data. In par-
ticular, in the latter study, patients with 
NPGN peritonitis were a similar age to 
those with Gram-positive peritonitis and 
had a lower rate of diabetes.1,2
Against this background, some new 
aspects of Gram-negative peritonitis 
are worth considering. Th e recent rand-
omized controlled trial by Bernardini et 
al. suggests that, as compared with stand-
ard therapy with mupirocin, topical gen-
tamicin applied to the exit site decreases 
both peritonitis and exit site infections 
secondary to Gram-negative organisms.6 
Although the study was small, the fi nd-
ings achieved statistical signifi cance, and 
there was a notable diff erence between the 
two groups in NPGN peritonitis, with the 
rates being 0.02 per patient year with gen-
tamicin versus 0.11 with mupirocin. Th ese 
results are the fi rst indication that there 
is a simple clinical intervention that can 
reduce rates of Gram-negative peritonitis. 
Th ey also suggest that NPGN peritonitis 
is acquired by the pericatheter route to a 
greater degree than might have been sus-
pected, which is encouraging in that such 
cases are probably more amenable to pre-
vention than cases acquired enterically.
Szeto et al.’s data on Gram-nega-
tive organisms that produce extended-
spectrum β-lactamases (ESBLs) are also 
interesting.1 ESBLs are plasmid-encoded 
β-lactamases that can hydrolyze penicil-
lins, cephalosporins, and monobactams.7 
Th ey are most oft en produced by entero-
bacteria such as Escherichia coli and 
Klebsiella pneumoniae and were first 
noted as signifi cant clinical pathogens in 
the 1990s, perhaps in response to wide-
spread use of cephalosporins. Co-treat-
ment with β-lactamase inhibitors such as 
clavulanic acid may not be suffi  cient, and 
the preferred option is the use of expen-
sive carbapenems such as imipenem. 
ESBLs may be diffi  cult to identify in the 
hospital microbiology laboratory, and 
our knowledge of their role in PD-related 
peritonitis is quite limited. Szeto et al.’s 
study1 indicates that ESBLs account for 
about 7% of the peritonitis cases due to 
E. coli and Klebsiella that have been seen 
in their center over the past 5 years. Con-
trary to expectation, these cases did not 
have notably worse outcomes than stand-
ard cases, but another recent paper from 
Hong Kong reports markedly higher 
rates of treatment failure and death in 
peritonitis due to ESBL-producing E. coli 
compared to conventional E. coli.8 Phy-
sicians and microbiologists dealing with 
PD patients need to be aware of ESBL-
producing organisms.
Finally, a word should be said about 
the enormous contribution that has 
been made to clinical research in PD 
over the past decade by investigators from 
Hong Kong. In areas as diverse as nutri-
tion, adequacy, and peritonitis, clinical 
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investigators from Hong Kong have been 
able to use their large population of PD 
patients and their high rate of retention 
on the modality to do excellent clinical 
studies and draw important conclusions. 
Th e present paper continues this tradi-
tion and is a further useful addition to 
the literature.
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